Epigenetic multiple modulators

Current Topics in Medicinal Chemistry

Volumn 11, Issue 22, 2011, Pages 2749-2787

  Álvarez, Rosana ^a   Altucci, Lucia ^b   Gronemeyer, Hinrich ^c   de Lera, Angel R ^a  

^a UNIVERSITY OF VIGO   (Spain)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Cancer; Chromatin; DNA; Enzyme inhibitors; Epigenetics; Histones; Multiple ligands

Indexed keywords

3 (3,5 DIBROMO 4 HYDROXYBENZYLIDENE) 1,3 DIHYDRO 5 IODO 2 INDOLONE; ABEXINOSTAT; ANACARDIC ACID; ANTINEOPLASTIC AGENT; APICIDIN; BELINOSTAT; BUTYRIC ACID; CURCUMIN; DACINOSTAT; DIFERULOYLMETHANE CURCUMIN; ENTINOSTAT; ENZYME INHIBITOR; GIVINOSTAT; HISTONE DEACETYLASE; HYDRALAZINE; KENPAULLONE; MOCETINOSTAT; PANOBINOSTAT; PHLOROGLUCINOL GARCINOL; PLUMBAGIN; ROMIDEPSIN; SIRTINOL; SIRTUIN; SURAMIN; TACEDINALINE; TRICHOSTATIN A; TUBACIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT;

ACETYLATION; ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; B CELL LYMPHOMA; CUTANEOUS T CELL LYMPHOMA; DIARRHEA; DRUG ACTIVITY; DRUG BINDING; DRUG DESIGN; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; EPIGENETICS; GENE THERAPY; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; METHYLATION; MULTIFACTORIAL GENETIC DISORDER; MULTIPLE MYELOMA; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; PHARMACOPHORE; PREDICTIVE VALUE; RACEMIC MIXTURE; REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANIMALS; ENZYME INHIBITORS; ENZYMES; EPIGENESIS, GENETIC; EPIGENOMICS; HUMANS; LIGANDS;

EID: 82055170387     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611798184436     Document Type: Review

References (235)

1. Allis, C. D.; Jenuwein, T.; Reinberg, D.; Caparros, M.-L. Epigenetics. Cold Spring Harbor Laboratory Press: Cold Spring Harbor (NY), 2007.
2. Hanna, J.; Carey, B. W.; Jaenisch, R. Reprogramming of somatic cell identity. Cold Spring Harb. Symp. Quant. Biol., 2008, 73, 147-155.
3. Broske, A. M.; Vockentanz, L.; Kharazi, S.; Huska, M. R.; Mancini, E.; Scheller, M.; Kuhl, C.; Enns, A.; Prinz, M.; Jaenisch, R.; Nerlov, C.; Leutz, A.; Andrade-Navarro, M. A.; Jacobsen, S. E.; Rosenbauer, F. DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction. Nat. Genet., 2009, 41, 1207-1215.
4. Feinberg, A. P. Phenotypic plasticity and the epigenetics of human disease. Nature, 2007, 447, 433-440.
5. Esteller, M. Epigenetics in cancer. N. Engl. J. Med., 2008, 358, 1148-1159.
6. Feinberg, A. P.; Vogelstein, B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature, 1983, 301, 89-92.
7. Bienvenu, T.; Chelly, J. Molecular genetics of Rett syndrome: when DNA methylation goes unrecognized. Nat. Rev. Genet., 2006, 7, 415-426.
8. Petrij, F.; Giles, R. H.; Dauwerse, H. G.; Saris, J. J.; Hennekam, R. C.; Masuno, M.; Tommerup, N.; van Ommen, G. J.; Goodman, R. H.; Peters, D. J. Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature, 1995, 376, 348-351.
9. Javierre, B. M.; Fernandez, A. F.; Richter, J.; Al-Shahrour, F.; Martin-Subero, J. I.; Rodríguez- Ubreva, J.; Berdasco, M.; Fraga, M. F.; O'Hanlon, T. P.; Rider, L. G.; Jacinto, F. V.; Lopez- Longo, F. J.; Dopazo, J.; Forn, M.; Peinado, M. A.; Carreno, L.; Sawalha, A. H.; Harley, J. B.; Siebert, R.; Esteller, M.; Miller, F. W.; Ballestar, E. Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res., 2010, 20, 170-179.
10. Baranzini, S. E.; Mudge, J.; van Velkinburgh, J. C.; Khankhanian, P.; Khrebtukova, I.; Miller, N. A.; Zhang, L.; Farmer, A. D.; Bell, C. J.; Kim, R. W.; May, G. D.; Woodward, J. E.; Caillier, S. J.; McElroy, J. P.; Gomez, R.; Pando, M. J.; Clendenen, L. E.; Ganusova, E. E.; Schilkey, F. D.; Ramaraj, T.; Khan, O. A.; Huntley, J. J.; Luo, S.; Kwok, P. Y.; Wu, T. D.; Schroth, G. P.; Oksenberg, J. R.; Hauser, S. L.; Kingsmore, S. F. Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis. Nature, 2010, 464, 1351-1356.
11. DeBaun, M. R.; Niemitz, E. L.; McNeil, D. E.; Brandenburg, S. A.; Lee, M. P.; Feinberg, A. P. Epigenetic alterations of H19 and LIT1 distinguish patients with Beckwith-Wiedemann syndrome with cancer and birth defects. Am. J. Hum. Genet., 2002, 70, 604-611.
12. Krivtsov, A. V.; Armstrong, S. A. MLL translocations, histone modifications and leukaemia stem-cell development. Nat. Rev. Cancer, 2007, 7, 823-833.
13. Chen, J.; Odenike, O.; Rowley, J. D. Leukaemogenesis: more than mutant genes. Nat. Rev. Cancer, 2010, 10, 23-36.
14. Risch, A.; Plass, C. Lung cancer epigenetics and genetics. Int. J. Cancer, 2008, 123, 1-7.
15. Levenson, V. V. DNA methylation as a universal biomarker. Expert Rev. Mol. Diagn., 2010, 10, 481-488.
16. Figueroa, M. E.; Lugthart, S.; Li, Y.; Erpelinck-Verschueren, C.; Deng, X.; Christos, P. J.; Schifano, E.; Booth, J.; van Putten, W.; Skrabanek, L.; Campagne, F.; Mazumdar, M.; Greally, J. M.; Valk, P. J.; Lowenberg, B.; Delwel, R.; Melnick, A. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell, 2010, 17, 13-27.
17. Garcia-Manero, G.; Yang, H.; Kuang, S. Q.; O'Brien, S.; Thomas, D.; Kantarjian, H. Epigenetics of acute lymphocytic leukemia. Semin. Hematol., 2009, 46, 24-32.
18. Varambally, S.; Cao, Q.; Mani, R. S.; Shankar, S.; Wang, X.; Ateeq, B.; Laxman, B.; Cao, X.; Jing, X.; Ramnarayanan, K.; Brenner, J. C.; Yu, J.; Kim, J. H.; Han, B.; Tan, P.; Kumar-Sinha, C.; Lonigro, R. J.; Palanisamy, N.; Maher, C. A.; Chinnaiyan, A. M. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science, 2008, 322, 1695-1699.
19. Kleer, C. G.; Cao, Q.; Varambally, S.; Shen, R.; Ota, I.; Tomlins, S. A.; Ghosh, D.; Sewalt, R. G.; Otte, A. P.; Hayes, D. F.; Sabel, M. S.; Livant, D.; Weiss, S. J.; Rubin, M. A.; Chinnaiyan, A. M. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl. Acad. Sci. USA, 2003, 100, 11606-11611.
20. Varambally, S.; Dhanasekaran, S. M.; Zhou, M.; Barrette, T. R.; Kumar-Sinha, C.; Sanda, M. G.; Ghosh, D.; Pienta, K. J.; Sewalt, R. G.; Otte, A. P.; Rubin, M. A.; Chinnaiyan, A. M. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature, 2002, 419, 624-629.
21. Daujat, S.; Bauer, U. M.; Shah, V.; Turner, B.; Berger, S.; Kouzarides, T. Crosstalk between CARM1 methylation and CBP acetylation on histone H3. Curr. Biol., 2002, 12, 2090-2097.
22. Vaissiere, T.; Sawan, C.; Herceg, Z. Epigenetic interplay between histone modifications and DNA methylation in gene silencing. Mutat. Res., 2008, 659, 40-48.
23. Nebbioso, A.; Clarke, N.; Voltz, E.; Germain, E.; Ambrosino, C.; Bontempo, P.; Alvarez, R.; Schiavone, E. M.; Ferrara, F.; Bresciani, F.; Weisz, A.; de Lera, A. R.; Gronemeyer, H.; Altucci, L. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat. Med., 2005, 11, 77-84.
24. Pruitt, K.; Zinn, R. L.; Ohm, J. E.; McGarvey, K. M.; Kang, S. H.; Watkins, D. N.; Herman, J. G.; Baylin, S. B. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet, 2006, 2, e40.
25. Apsel, B.; Blair, J. A.; Gonzalez, B.; Nazif, T. M.; Feldman, M. E.; Aizenstein, B.; Hoffman, R.; Williams, R. L.; Shokat, K. M.; Knight, Z. A. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat. Chem. Biol., 2008, 4, 691-699.
26. Gronemeyer, H.; Altucci, L.; de Lera, Á. R.; Stunnenberg, H. G. Novel derivatives of psammaplin A, a method for their synthesis and their use for the prevention or treatment of cancer. WO2008/125988 A1.
27. Finch, J. T.; Lutter, L. C.; Rhodes, D.; Brown, R. S.; Rushton, B.; Levitt, M.; Klug, A. Structure of nucleosome particles of chromatin. Nature, 1977, 269, 29-36.
28. Sippl, W.; Jung, M. Epigenetic Targets in Drug Discovery. Vol. 42, Wiley-VCH: Weinheim, 2009.
29. Szyf, M. Epigenetics, DNA methylation and chromatin modifying drugs. Ann. Rev. Pharmacol. Toxicol., 2009, 49, 243-263.
30. Chatterjee, C.; Muir, T. W. Chemical approaches for studying histone modifications. J. Biol. Chem., 2010, 285, 11045-11050.
31. Allis, C. D.; Berger, S. L.; Cote, J.; Dent, S.; Jenuwein, T.; Kouzarides, T.; Pillus, L.; Reinberg, D.; Shi, Y.; Shiekhattar, R.; Shilatifard, A.; Workman, J. L.; Zhang, Y. New nomenclature for chromatin-modifying enzymes. Cell, 2007, 131, 633-636.
32. Wang, Z.; Zang, C.; Cui, K.; Schones, D. E.; Barski, A.; Peng, W.; Zhao, K. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell, 2009, 138, 1019-1031.
33. Choudhary, C.; Kumar, C.; Gnad, F.; Nielsen, M. L.; Rehman, M.; Walther, T. C.; Olsen, J. V.; Mann, M. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science, 2009, 325, 834-840.
34. Zhao, S.; Xu, W.; Jiang, W.; Yu, W.; Lin, Y.; Zhang, T.; Yao, J.; Zhou, L.; Zeng, Y.; Li, H.; Li, Y.; Shi, J.; An, W.; Hancock, S. M.; He, F.; Qin, L.; Chin, J.; Yang, P.; Chen, X.; Lei, Q.; Xiong, Y.; Guan, K.-L. Regulation of cellular metabolism by protein lysine acetylation. Science, 2010, 327, 1000-1004.
35. Wang, Q.; Zhang, Y.; Yang, C.; Xiong, H.; Lin, Y.; Yao, J.; Li, H.; Xie, L.; Zhao, W.; Yao, Y.; Ning, Z.-B.; Zeng, R.; Xiong, Y.; Guan, K.-L.; Zhao, S.; Zhao, G.-P. Acetylation of metabolic enzymes coordinates carbon source utilization and metabolic flux. Science, 2010, 327, 1004-1007.
36. Buchwald, M.; Krömer, O. H.; Heinzel, T. HDACi - Targets beyond chromatin. Cancer Lett., 2009, 280, 160-167.
37. Peleg, S.; Sananbenesi, F.; Zovoilis, A.; Burkhardt, S.; Bahari- Javan, S.; Agis-Balboa, R. C.; Cota, P.; Wittnam, J. L.; Gogol- Doering, A.; Opitz, L.; Salinas-Riester, G.; Dettenhofer, M.; Kang, H.; Farinelli, L.; Chen, W.; Fischer, A. Altered histone acetylation Is associated with age-dependent memory impairment in mice. Science, 2010, 328, 753-756.
38. Marks, P. A.; Rifkind, R. A.; Richon, V. M.; Breslow, R.; Miller, T.; Kelly, W. K. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer, 2001, 1, 194-202.
39. Dekker, F. J.; Haisma, H. J. Histone acetyl transferases as emerging drug targets. Drug Disc. Today, 2009, 14, 942-948.
40. Minucci, S.; Pelicci, P. G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer, 2006, 6, 38-51.
41. Villagra, A.; Sotomayor, E. M.; Seto, E. Histone deacetylases and the immunological network: implications in cancer and inflammation. Oncogene, 2010, 29, 157-173.
42. Glauben, R.; Sonnenberg, E.; Zeitz, M.; Siegmund, B. HDAC inhibitors in models of inflammation-related tumorigenesis. Cancer Lett., 2009, 280, 154-159.
43. Botrugno, O. A.; Santoro, F.; Minucci, S. Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer. Cancer Lett., 2009, 280, 134-144.
44. Bolden, J. E.; Peart, M. J.; Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors. Nature Rev. Drug Discov., 2006, 5, 769-784.
45. Frew, A. J.; Johnstone, R. W.; Bolden, J. E. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett., 2009, 280, 125-133.
46. Hodawadekar, S. C.; Marmorstein, R. Chemistry of acetyl transfer by histone modifying enzymes: structure, mechanism and implications for effector design. Oncogene, 2007, 26, 5528-5540.
47. Romier, C.; Wurtz, J.-M.; Renaud, J.-P.; Cavarelli, J. Structural biology of epigenetic targets. In Epigenetics Targets in Drug Discovery, Sippl, W.; Jung, M., Eds. Wiley-VCH: Weinheim, 2009; pp 23-56.
48. Liu, X.; Wang, L.; Zhao, K.; Thompson, P. R.; Hwang, Y.; Marmorstein, R.; Cole, P. A. The structural basis of protein acetylation by the p300/CBP transcriptional coactivator. Nature, 2008, 451, 846-850.
49. von Wantoch Rekowski, M.; Giannis, A. Inhibitors of histone acetyl transferases: Discovery and biochemical perspectives. In Epigenetics Targets in Drug Discovery, Sippl, W.; Jung, M., Eds. Wiley-VCH: Weinheim, 2009; pp 243-250.
50. Wu, J.; Xie, N.; Wu, Z.; Zhang, Y.; Zheng, Y. G. Bisubstrate inhibitors of the MYST HATs Esa1 and Tip60. Bioorg. Med. Chem., 2009, 17, 1381-1386.
51. Ravindra, K. C.; Selvi, B. R.; Arif, M.; Reddy, B. A. A.; Thanuja, G. R.; Agrawal, S.; Pradhan, S. K.; Nagashayana, N.; Dasgupta, D.; Kundu, T. K. Inhibition of lysine acetyltransferase KAT3B/p300 activity by a naturally occurring hydroxynaphthoquinone, plumbagin. J. Biol. Chem., 2009, 284, 24453-24464.
52. Arif, M.; Pradhan, S. K.; G R, T.; Vedamurthy, B. M.; Agrawal, S.; Dasgupta, D.; Kundu, T. K. Mechanism of p300 specific histone acetyltransferase inhibition by small molecules. J. Med. Chem., 2009, 52, 267-277.
53. Bowers, E. M.; Yan, G.; Mukherjee, C.; Orry, A.; Wang, L.; Holbert, M. A.; Crump, N. T.; Hazzalin, C. A.; Liszczak, G.; Yuan, H.; Larocca, C.; Saldanha, S. A.; Abagyan, R.; Sun, Y.; Meyers, D. J.; Marmorstein, R.; Mahadevan, L. C.; Alani, R. M.; Cole, P. A. Virtual ligand screening of the p300/CBP histone acetyltransferase: Identification of a selective small molecule inhibitor. Chem. Biol., 2010, 17, 471-482.
54. Heinke, R.; Uciechowska, U.; Sippl, W. Computer- and structurebased lead identification for epigenetic targets. In Epigenetics Targets in Drug Discovery, Sippl, W.; Jung, M., Eds. Wiley- VCH: Weinheim, 2009; pp 57-85.
55. Dal Piaz, F.; Tosco, A.; Eletto, D.; Piccinelli, A. L.; Moltedo, O.; Franceschelli, S.; Sbardella, G.; Remondelli, P.; Rastrelli, L.; Vesci, L.; Pisano, C.; De Tommasi, N. The identification of a novel natural activator of p300 histone acetyltranferase provides new insights into the modulation mechanism of this enzyme. ChemBioChem, 2010, 11, 818-827.
56. Zhang, Y.; Fang, H.; Jiao, J.; Wu, W. The Structure and function of histone deacetylases: The target for anticancer therapy. Curr. Med. Chem., 2008, 15, 2840-2849.
57. Estiu, G.; Greenberg, E.; Harrison, C. B.; Kwiatkowski, N. P.; Mazitschek, R.; Bradner, J. E.; Wiest, O. Structural origin of selectivity in class II-selective histone deacetylase inhibitors. J. Med. Chem., 2008, 51, 2898-2906.
58. Grozinger, C. M.; Schreiber, S. L. Deacetylase enzymes: Biological functions and the use of small-molecule inhibitors. Chem. Biol., 2002, 9, 3-16.
59. Corminboeuf, C.; Hu, P.; Tuckerman, M. E.; Zhang, Y. Unexpected deacetylation mechanism suggested by a density functional theory QM/MM study of histone-deacetylase-like protein. J. Am. Chem. Soc., 2006, 128, 4530-4531.
60. Finnin, M. S.; Donigian, J. R.; Cohen, A.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.; Breslow, R.; Pavletich, N. P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature, 1999, 401, 188-193.
61. Jones, P. Histone Deacetylase inhibitors. In Epigenetics Targets in Drug Discovery, Sippl, W.; Jung, M., Eds. Wiley-VCH: Weinheim, 2009; pp 185-223.
62. Paris, M.; Porcelloni, M.; Binaschi, M.; Fattori, D. Histone deacetylase inhibitors: From bench to clinic. J. Med. Chem., 2008, 51, 1505-1529.
63. Miller, T. A.; Witter, D. J.; Belvedere, S. Histone deacetylase inhibitors. J. Med. Chem., 2003, 46, 5097-5114.
64. Bradner, J. E.; West, N.; Grachan, M. L.; Greenberg, E. F.; Haggarty, S. J.; Warnow, T.; Mazitschek, R. Chemical phylogenetics of histone deacetylases. Nat. Chem. Biol., 2010, 6, 238-243.
65. Vanommeslaeghe, K.; Loverix, S.; Geerlings, P.; Tourwe, D. DFTbased ranking of zinc-binding groups in histone deacetylase inhibitors. Bioorg. Med. Chem., 2005, 13, 6070.
66. Wang, D.; Helquist, P.; Wiest, O. Zinc Binding in HDAC inhibitors: A DFT Study. J. Org. Chem., 2008, 72, 5446-5449.
67. Gantt, S. L.; Gattis, S. G.; Fierke, C. A. Catalytic activity and inhibition of human histone deacetylase 8 is dependent on the identity of the active site metal ion. Biochemistry, 2006, 45, 6170-6178.
68. Pérez-Balado, C.; Rodríguez-Graña, P.; Nebiosso, A.; Minichiello, A.; Miceli, M.; Altucci, L.; de Lera, A. R. Bispyridinium dienes, a novel class of histone deacetylase inhibitors with selective activities. J. Med. Chem., 2007, 50, 2497-2505.
69. Finkel, T.; Deng, C.-X.; Mostoslavsky, R. Recent progress in the biology and physiology of sirtuins. Nature, 2009, 460, 587-591.
70. Longo, V. D.; Kennedy, B. K. Sirtuins in aging and age-related disease. Cell, 2006, 126, 257-268.
71. Guarente, L. Sirtuins as potential targets for metabolic syndrome. Nature, 2006, 444, 868-874.
72. Liu, T.; Liu, P. Y.; Marshall, G. M. The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res., 2009, 69, 1702-1705.
73. Zhong, L.; D'Urso, A.; Toiber, D.; Sebastian, C.; Henry, R. E.; Vadysirisack, D. D.; Guimaraes, A.; Marinelli, B.; Wikstrom, J. D.; Nir, T.; Clish, C. B.; Vaitheesvaran, B.; Iliopoulos, O.; Kurland, I.; Dor, Y.; Weissleder, R.; Shirihai, O. S.; Ellisen, L. W.; Espinosa, J. M.; Mostoslavsky, R. The Histone deacetylase Sirt6 regulates glucose homeostasis via Hif1±. Cell 2010, 140, 280-293.
74. Lavu, S.; Boss, O.; Elliot, P. J.; Lambert, P. D. Sirtuins-novel therapeutic targets to treat age- associated disorders. Nat. Rev. Drug Discov., 2008, 7, 841-853.
75. Smith, B. C.; Hallows, W. C.; Denu, J. M. Mechanisms and molecular probes of sirtuins. Chem. Biol., 2008, 15, 1002-1013.
76. Li, H.; Simon, J. A.; Bedalov, A. NAD-dependent deacetylases as therapeutic targets. In Epigenetics Targets in Drug Discovery, Sippl, W.; Jung, M., Eds. Wiley-VCH: Weinheim, 2009; pp 225-242.
77. Hawse, W. F.; Wolberger, C. Structure-based mechanism of ADPribosylation by sirtuins. J. Biol. Chem., 2009, 284, 33654-33661.
78. Kim, H.-S.; Patel, K.; Muldoon-Jacobs, K.; Bisht, K. S.; Aykin- Burns, N.; Pennington, J. D.; van der Meer, R.; Nguyen, P.; Savage, J.; Owens, K. M.; Vassilopoulos, A.; Ozden, O.; Park, S.- H.; Singh, K. K.; Abdulkadir, S. A.; Spitz, D. R.; Deng, C.-X.; Gius, D. SIRT3 is a mitochondria- localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell, 2010, 17, 41-52.
79. Jin, L.; Wei, W.; Jiang, Y.; Peng, H.; Cai, J.; Mao, C.; Dai, H.; Choy, W.; Bemis, J. E.; Jirousek, M. R.; Milne, J. C.; Westphal, C. H.; Perni, R. B. Crystal structures of human SIRT3 displaying substrate-induced conformational changes. J. Biol. Chem., 2009, 284, 24394-24405.
80. Zhao, K.; Harshaw, R.; Chai, X.; Marmorstein, R. Structural basis for nicotinamide cleavage and ADP-ribose transfer by NAD+- dependent Sir2 histone/protein deacetylases. Proc. Natl. Acad. Sci. USA, 2004, 101, 8563-8568.
81. Ávalos, J. L.; Boeke, J. D.; Wolberger, C. Structural basis for the mechanism and regulation of Sir2 enzymes. Mol. Cell, 2004, 13, 639-648.
82. Hawse, W. F.; Hoff, K. G.; Fatkins, D. G.; Daines, A.; Zubkova, O. V.; Schramm, V. L.; Zheng, W.; Wolberger, C. Structural insights into intermediate steps in the Sir2 seacetylation reaction. Structure, 2008, 16, 1368-1377.
83. Hu, P.; Wang, S.; Zhang, Y. Highly Dissociative and concerted mechanism for the nicotinamide cleavage reaction in Sir2Tm enzyme suggested by ab initio QM/MM molecular dynamics simulations. J. Am. Chem. Soc., 2008, 130, 16721-16728.
84. Smith, B. C.; Denu, J. M. Sir2 deacetylases exhibit nucleophilic participation of acetyl-lysine in NAD+ cleavage. J. Am. Chem. Soc., 2007, 129, 5802-5803.
85. Suzuki, T.; Asaba, T.; Imai, E.; Tsumoto, H.; Nakagawa, H.; Miyata, N. Identification of cell- active non-peptide sirtuin inhibitor containing N-thioacetyl lysine. Bioorg. Med. Chem. Lett., 2009, 19, 5670-5672.
86. Asaba, T.; Suzuki, T.; Ueda, R.; Tsumoto, H.; Nakagawa, H.; Miyata, N. Inhibition of human sirtuins by in situ generation of an acetylated lysine-ADP-ribose conjugate. J. Am. Chem. Soc., 2009, 131, 6989-6996.
87. Kiviranta, P. H.; Suuronen, T.; Wallén, E. A. A.; Leppänen, J.; Tervonen, J.; Kyrylenko, S.; Salminen, A.; Poso, A.; Jarho, E. M. N e -Thioacetyl-lysine-containing tri-, tetra-, and pentapeptides as SIRT1 and SIRT2 inhibitors. J. Med. Chem., 2009, 52, 2153-2156.
88. Chakrabarty, S. P.; Ramapanicker, R.; Mishra, R.; Chandrasekaran, S.; Balaram, H. Development and characterization of lysine based tripeptide analogues as inhibitors of Sir2 activity. Bioorg. Med. Chem., 2009, 17, 8060-8072.
89. Gutiérez, M.; Andrianasolo, E. H.; Shin, W. K.; Goeger, D. E.; Yokochi, A.; Schemies, J.; Jung, M.; France, D.; Cornell-Kennon, S.; Lee, E.; Gerwick, W. H. Structural and synthetic investigations of tanikolide dimer, a SIRT2 selective inhibitor, and tanikolide seco-acid from the Madagascar marine cyanobacterium Lyngbya majuscula. J. Org. Chem., 2009, 74, 5267-5275.
90. Trapp, J.; Meier, R.; Hongwiset, D.; Kassack, M. U.; Sippl, W.; Jung, M. Structure-activity studies on suramin analogues as inhibitors of NAD+-dependent histone deacetylases (Sirtuins). ChemMedChem, 2007, 2, 1419-1431.
91. Kiviranta, P. H.; Salo, H. S.; Leppänen, J.; Rinne, V. M.; Kyrylenko, S.; Kuusisto, E.; Suuronen, T.; Salminen, A.; Poso, A.; Lahtela-Kakkonen, M.; Wallén, E. A. A. Characterization of the binding properties of SIRT2 inhibitors with a N-(3- phenylpropenoyl)-glycine tryptamide backbone. Bioorg. Med. Chem., 2008, 16, 8054-8062.
92. Suzuki, T.; Imai, K.; Imai, E.; Iida, S.; Ueda, R.; Tsumoto, H.; Nakagawa, H.; Miyata, N. Design, synthesis, enzyme inhibition, and tumor cell growth inhibition of 2-anilinobenzamide derivatives as SIRT1 inhibitors. Bioorg. Med. Chem., 2009, 17, 5900-5905.
93. Lain, S.; Hollick, J. J.; Campbell, J.; Staples, O. D.; Higgins, M.; Aoubala, M.; McCarthy, A.; Appleyard, V.; Murray, K. E.; Baker, L.; Thompson, A.; Mathers, J.; Holland, S. J.; Stark, M. J. R.; Pass, G.; Woods, J.; Lane, D. P.; Westwood, N. J. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell, 2008, 13, 454-463.
94. Zhang, Y.; Au, Q.; Zhang, M.; Barber, J. R.; Ng, S. C.; Zhang, B. Identification of a small molecule SIRT2 inhibitor with selective tumor cytotoxicity. Biochem. Biophys. Res. Commun., 2009, 386, 729-733.
95. Trapp, J.; Jochum, A.; Meier, R.; Saunders, L.; Marshall, B.; Kunick, C.; Verdin, E.; Goekjian, P.; Sippl, W.; Jung, M. Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition. J. Med. Chem., 2006, 49, 7307-7316.
96. Huber, K.; Schemies, J.; Uciechowska, U.; Wagner, J. M.; Rumpf, T.; Lewrick, F.; Süss, R.; Sippl, W.; Jung, M.; Bracher, F. Novel 3- arylideneindolin-2-ones as inhibitors of NAD+- dependent histone deacetylases (Sirtuins). J. Med. Chem., 2010, 53, 1383-1386.
97. Medda, F.; Russell, R. J. M.; Higgins, M.; McCarthy, A. R.; Campbell, J.; Slawin, A. M. Z.; Lane, D. P.; Lain, S.; Westwood, N. J. Novel cambinol analogs as sirtuin inhibitors: Synthesis, biological evaluation, and rationalization of activity. J. Med. Chem., 2009, 52, 2673-2682.
98. Rotili, D.; Tarantino, D.; Carafa, V.; Lara, E.; Meade, S.; Botta, G.; Nebbioso, A.; Schemies, J.; Jung, M.; Kazantsev, A. G.; Esteller, M.; Fraga, M. F.; Altucci, L.; Mai, A. Identification of tri- and tetracyclic pyrimidinediones as Sirtuin inhibitors. ChemMedChem, 2010, 5, 674-677.
99. Lara, E.; Mai, A.; Calvanese, V.; Altucci, L.; López-Nieva, P.; Martínez-Chantar, M. L.; Varela- Rey, M.; Rotili, D.; Nebbioso, A.; Ropero, S.; Montoya, G.; Oyarzabal, J.; Velasco, S.; Serrano, M.; Witt, M.; Villar-Garea, A.; Inhof, A.; Mato, J. M.; Esteller, M.; Fraga, M. F. Salermide, a Sirtuin inhibitor with a strong cancerspecific proapoptotic effect. Oncogene, 2009, 28, 781-791.
100. Neugebauer, R. C.; Uchiechowska, U.; Meier, R.; Hruby, H.; Valkov, V.; Verdin, E.; Sippl, W.; Jung, M. Structure and activity studies on splitomicin derivatives as Sirtuin inhibitors and computational prediction of binding mode. J. Med. Chem., 2008, 51, 1203-1213.
101. Huhtiniemi, T.; Suuronen, T.; Rinne, V. M.; Wittekindt, C.; Lahtela-Kakkonen, M.; Jarho, E.; Wallërik, A. A.; Salminen, A.; Poso, A.; Leppänen, J. Oxadiazole-carbonylaminothioureas as SIRT1 and SIRT2 inhibitors. J. Med. Chem., 2008, 51, 4377-4380.
102. Tavares, J.; Ouaissi, A.; Kong Tho Lin, P.; Loureiro, I.; Kaur, S.; Roy, N.; Cordeiro da Silva, A. Bisnaphthalimidopropyl derivatives as inhibitors of Leishmania SIR2 related protein. ChemMedChem, 2010, 5, 140-147.
103. Pacholec, M.; Bleasdale, J. E.; Chrunyk, B.; Cunningham, D.; Flynn, D.; Garofalo, R. S.; Griffith, D.; Griffor, M.; Loulakis, P.; Pabst, B.; Qiu, X.; Stockman, B.; Thanabal, V.; Varghese, A.; Ward, J.; Withka, J.; Ahn, K. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J. Biol. Chem., 2010, 285, 8340-8351.
104. Ooi, S. K. T.; Bestor, T. H. The colorful history of active DNA demethylation. Cell, 2008, 133, 1145-1148.
105. Esteller, M. CpG island hypermethylation and tumor suppressor genes: A booming present, a brighter future. Oncogene, 2002, 21, 5427-5440.
106. Brown, R.; Strathdee, G. Epigenomics and epigenetic therapy of cancer. Trends Mol. Med., 2002, 8, S43-S48.
107. Klimasauskas, S.; Kumar, S.; Roberts, R. J.; Cheng, X. HhaI methyltransferase flips its target base out of the DNA helix. Cell, 1994, 76, 357-369.
108. Verdine, G. L. The flip side of DNA methylation. Cell, 1994, 76, 197.
109. Sippl, W.; Jung, M. DNA Methyltransferase inhibitors. In: Epigenetics Targets in Drug Discovery, Sippl, W.; Jung, M., Eds. Wiley-VCH: Weinheim, 2009; pp 163-183.
110. Yoo, C. B.; Valente, R.; Congiatu, C.; Gavazza, F.; Angel, A.; Siddiqui, M. A.; Jones, P. A.; McGuigan, C.; Márquez, V. E. Activation of p16 gene silenced by DNA methylation in cancer cells by phosphoramidate derivatives of 2'-Deoxyzebularine. J. Med. Chem. 2008, 51, 7593-7601.
111. Kuck, D.; Singh, N.; Lyko, F.; Medina-Franco, J. L. Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg. Med. Chem., 2010, 18, 822-829.
112. Datta, J.; Ghoshal, K.; Denny, W. A.; Gamage, S. A.; Brooke, D. G.; Phiasivongsa, P.; Redkar, S.; Jacob, S. T. A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation. Cancer Res., 2009, 69, 4277-4285.
113. Singh, N.; Dueñas-González, A.; Lyko, F.; Medina-Franco, J. L. Molecular modeling and molecular dynamic studies of hydralazine with human DNA methyltransferase 1. ChemMedChem, 2009, 4, 792-799.
114. Kouzarides, T. Histone methylation in transcriptional control. Curr. Op. Genetic. Develop., 2002, 12, 198-209.
115. Shilatifard, A. Chromatin modifications by methylation and ubiquitination: Implications in the regulation of gene expression. Annu. Rev. Biochem., 2006, 75, 243-269.
116. Bracken, A. P.; Helin, K. Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat. Rev. Cancer, 2009, 9, 773-784.
117. Morey, L.; Helin, K. Polycomb group protein-mediated repression of transcription. Trends Biochem. Sci., 2010, 35, 323-332.
118. Spannhoff, A.; Hauser, A.-T.; Heinke, R.; Sippl, W.; Jung, M. The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors. ChemMedChem, 2009, 4, 1568-1582.
119. Copeland, R. A.; Solomon, M. E.; Richon, V. M. Protein methyltransferases as a target class for drug discovery. Nat. Rev. Drug Discov., 2009, 8, 724-732.
120. Cheng, X.; Collins, R. E.; Zhang, X. Structural and sequence motifs of protein (histone) methylation enzymes Annu. Rev. Biophys. Biomol. Structure, 2005, 34, 267-294.
121. Marmorstein, R. Structure of SET domain proteins: a new twist on histone methylation. Trends Biochem. Sci., 2003, 28, 59-62.
122. Smith, B. C.; Denu, J. M. Chemical mechanisms of histone lysine and arginine modifications. Biochim. Biophys. Acta, 2009, 1789, 45-57.
123. Hu, P.; Zhang, Y. Catalytic mechanism and product specificity of the histone lysine methyltransferase SET7/9: An ab initio QM/MM-FE study with multiple initial structures. J. Am. Chem. Soc., 2006, 128, 1272-1278.
124. Hu, P.; Wang, S.; Zhang, Y. How do SET-domain protein lysine methyltransferases achieve the methylation state specificity? Revisited by ab initio QM/MM molecular dynamic simulations. J. Am. Chem. Soc., 2008, 130, 3806-3813.
125. Xu, Q.; Chu, Y.-z.; Guo, H.-B.; Smith, J. C.; Guo, H. Energy triplets for writing epigenetic marks: insights from QM/MM free energy simulations of protein methyl transferases. Chem. Eur. J., 2009, 15, 12596-12599.
126. Jung, M. Histone methyltransferases as novel drug targets. In: Epigenetics Targets in Drug Discovery, Sippl, W.; Jung, M., Eds. Wiley-VCH: Weinheim, 2009; pp 251-268.
127. Sun, F.; Chan, E.; Wu, Z.; Yang, X.; Marquez, V. E.; Yu, Q. Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells. Mol. Cancer Ther., 2009, 8, 3191-3202.
128. Chang, Y.; Zhang, X.; Horton, J. R.; Upadhyay, A. K.; Spannhoff, A.; Liu, J.; Snyde, J. P.; Bedford, M. T.; Cheng, X. Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX- 01294. Nat. Struct. Mol. Biol., 2009, 16, 312-317.
129. Liu, F.; Chen, X.; Allali-Hassani, A.; Quinn, A. M.; Wasney, G. A.; Dong, A.; Barsyte, D.; Kozieradzki, I.; Senisterra, G.; Chau, I.; Siarheyeva, A.; Kireev, D. B.; Jadhav, A.; Herold, J. M.; Frye, S. V.; Arrowsmith, C. H.; Brown, P. J.; Simeonov, A.; Vedadi, M.; Jin, J. Discovery of a 2,4-diamino-7-aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a. J. Med. Chem., 2009, 52, 7950-7953.
130. Bedford, M. T. Arginine methylation at a glance. J. Cell Sci., 2007, 120, 4243-4246.
131. Jenuwein, T. The epigenetic magic of histone lysine methylation. FEBS J., 2006, 273, 3121-3135.
132. Osborne, T.; WellerRoska, R. L.; Rajski, S. R.; Thompson, P. R. In situ generation of a bisubstrate analogue for protein arginine methyltransferase 1. J. Am. Chem. Soc., 2008, 130, 4574-4575.
133. Obianyo, O.; Causey, C. P.; Osborne, T. C.; Jones, J. E.; Lee, Y.- H.; Stallcup, M. R.; Thompson, P. R. A Chloroacetamidine-based inactivator of protein arginine methyltransferase 1: Design, synthesis, and in vitro and in vivo Evaluation. ChemBioChem, 2010, 11, 1219-1223.
134. Ragno, R.; Simeoni, S.; Castellano, S.; Vicidomini, C.; Mai, A.; Caroli, A.; Tramontano, A.; Bonaccini, C.; Trojer, P.; Bauer, I.; Brosch, G.; Sbardella, G. Small molecule inhibitors of histone arginine methyltransferases: Homology modeling, molecular docking, binding mode analysis, and biological evaluations. J. Med. Chem., 2007, 50, 1241-1253.
135. Heinke, R.; Spannhoff, A.; Meier, R.; Trojer, P.; Bauer, I.; Jung, M.; Sippl, W. Virtual screening and biological characterization of novel histone arginine methyltransferase PRMT1 inhibitors. ChemMedChem, 2009, 4, 69-77.
136. Castellano, S.; Milite, C.; Ragno, R.; Simeoni, S.; Mai, A.; Limongelli, V.; Novellino, E.; Bauer, I.; Brosch, G.; Spannhoff, A.; Cheng, D.; Bedford, M. T.; Sbardella, G. Design, synthesis and biological evaluation of carboxy analogues of arginine methyltransferase inhibitor 1 (AMI-1). ChemMedChem, 2010, 5, 398-414.
137. Mai, A.; Valente, S.; Cheng, D.; Perrone, A.; Ragno, R.; Simeoni, S.; Sbardella, G.; Brosch, G.; Nebbioso, A.; Conte, M.; Altucci, L.; Bedford, M. T. Synthesis and biological validation of novel histone/protein methyltransferase inhibitors. ChemMedChem, 2007, 2, 987-991.
138. Spannhoff, A.; Machmur, R.; Heinke, R.; Trojer, P.; Bauer, I.; Brosch, G.; Schule, R.; Hanefeld, W.; Sippl, W.; Jung, M. A novel arginine methyltransferase inhibitor with cellular activity. Bioorg. Med. Chem. Lett., 2007, 17, 4150-4153.
139. Wan, H.; Huynh, T.; Pang, S.; Geng, J.; Vaccaro, W.; Poss, M. A.; Trainor, G. L.; Lorenzi, M. V.; Gottardis, M.; Jayaraman, L.; Purandare, A. V. Benzo[d]imidazole inhibitors of coactivator associated arginine methyltransferase 1 (CARM1)-hit to lead studies. Bioorg. Med. Chem. Lett., 2009, 19, 5063-5066.
140. Selvi, B. R.; Batta, K.; Kishore, A. H.; Mantelingu, K.; Varier, R. A.; Balasubramanyam, K.; Pradhan, S. K.; Dasgupta, D.; Sriram, S.; Agrawal, S.; Kundu, T. K. Identification of a novel inhibitor of coactivator-associated arginine methyltransferase 1 (CARM1)- mediated methylation of histone H3 Arg-17. J. Biol. Chem., 2010, 285, 7143-7152.
141. Purandare, A. V.; Chen, Z.; Huynh, T.; Pang, S.; Geng, J.; Vaccaro, W.; Poss, M. A.; Oconnell, J.; Nowak, K.; Jayaraman, L. Pyrazole inhibitors of coactivator associated arginine methyltransferase 1 (CARM1). Bioorg. Med. Chem. Lett., 2008, 18, 4438-4441.
142. Allan, M.; Manku, S.; Therrien, E.; Nguyen, N.; Styhler, S.; Robert, M.-F.; Goulet, A.-C.; Petschner, A. J.; Rahil, G.; MacLeod, A. R.; DÈziel, R.; Besterman, J. M.; Nguyen, H.; Wahhab, A. NBenzyl- 1-heteroaryl-3-(trifluoromethyl)-1H-pyrazole-5- carboxamides as inhibitors of co- activator associated arginine methyltransferase 1 (CARM1). Bioorg. Med. Chem. Lett., 2009, 19, 1218-1223.
143. Therrien, E.; Larouche, G.; Manku, S.; Allan, M.; Nguyen, N.; Styhler, S.; Robert, M.-F.; Goulet, A.-C.; Besterman, J. M.; Nguyen, H.; Wahhab, A. 1,2-Diamines as inhibitors of co- activator associated arginine methyltransferase 1 (CARM1). Bioorg. Med. Chem. Lett., 2009, 19, 6725-6732.
144. Agger, K.; Christensen, J.; Cloos, P. A. C.; Helin, K. The emerging functions of histone demethylases. Curr. Op. Gen. Dev., 2008, 18, 159-168.
145. Anand, R.; Marmorstein, R. Structure and mechanism of lysinespecific demethylase enzymes. J. Biol. Chem., 2007, 282, 35425-35429.
146. Schneider, J.; Shilatifard, A. Histone demethylation by hydroxylation: Chemistry in action. ACS Chem. Biol., 2006, 1, 75-81.
147. Wang, Y.; Wysocka, J.; Sayegh, J.; Lee, Y. H.; Pertin, J. R.; Leonelli, L.; Sonbuchner, L. S.; McDonald, C. H.; Cook, R. G.; Dou, Y.; Roeder, R. G.; Clarke, S.; Stallcup, M. R.; Allis, C. D.; Coonrod, S. A. Human PAD4 regulates histone arginine methylation levels via demethylimination. Science, 2004, 306, 279-283.
148. Cuthbert, G. L.; Daujat, S.; Snowden, A. W.; Erdjument-Bromage, H.; Hagiwara, T.; Yamada, M.; Schneider, R.; Gregory, P. D.; Tempst, P.; Bannister, A. J.; Kouzarides, T. Histone deimination antagonizes arginine methylation Cell, 2004, 118, 545-553.
149. Fackelmayer, F. O. Protein arginine methyltransferases: Guardians of the Arg? Trends Biochem. Sci., 2005, 30, 666-671.
150. Clausen, R. P.; Pedersen, M. T.; Helin, K. Histone demethylases. In Epigenetics Targets in Drug Discovery, Sippl, W.; Jung, M., Eds. Wiley-VCH: Weinheim, 2009; pp 269-290.
151. Shi, Y.; Lan, F.; Matson, C.; Mulligan, P.; Whetstine, J. R.; Cole, P. A.; Casero, R. A.; Shi, Y. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell, 2004, 119, 941-953.
152. Metzger, E.; Wissmann, M.; Yin, N.; Muller, J. M.; Schneider, R.; Peters, A. H. F. M.; Gunther, T.; Buettner, R.; Schule, R. LSD1 demethylates repressive histone marks to promote androgenreceptor- dependent transcription. Nature, 2005, 437, 436-439.
153. Huang, J.; Sengupta, R.; Espejo, A. B.; Lee, M. G.; Dorsey, J. A.; Richter, M.; Opravil, S.; Shiekhattar, R.; Bedford, M. T.; Jenuwein, T.; Berger, S. L. p53 is regulated by the lysine demethylase LSD1. Nature, 2007, 449, 105-109.
154. Shilatifard, A. Chromatin modifications by methylation and ubiquitination: Implications in the regulation of gene expression. Ann. Rev. Biochem., 2006, 75, 243-269.
155. Karytinos, A.; Forneris, F.; Profumo, A.; Ciossani, G.; Battaglioli, E.; Binda, C.; Mattevi, A. A Novel mammalian flavin-dependent histone demethylase. J. Biol. Chem., 2009, 284, 17775-17782.
156. Yang, M.; Culhane, J. C.; Szewczuk, L. M.; Gocke, C. B.; Brautigam, C. A.; Tomchick, D. R.; Machius, M.; Cole, P. A.; Yu, H. Structural basis of histone demethylation by LSD1 revealed by suicide inactivation. Nat. Struct. Mol. Biol., 2007, 14, 535-539.
157. Culhane, J. C.; Szewczuk, L. M.; Liu, X.; Da, G.; Marmorstein, R.; Cole, P. A. A mechanism- based inactivator for histone demethylase LSD1. J. Am. Chem. Soc., 2006, 128, 4536-4537.
158. Ueda, R.; Suzuki, T.; Mino, K.; Tsumoto, H.; Nakagawa, H.; Hasegawa, M.; Sasaki, R.; Mizukami, T.; Miyata, N. Identification of cell-active lysine specific demethylase 1-selective inhibitors. J. Am. Chem. Soc., 2009, 131, 17536-17537.
159. Binda, C.; Valente, S.; Romanenghi, M.; Pilotto, S.; Cirilli, R.; Karytinos, A.; Ciossani, G.; Botrugno, O. A.; Forneris, F.; Tardugno, M.; Edmondson, D. E.; Minucci, S.; Mattevi, A.; Mai, A. Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2. J. Am. Chem. Soc., 2010, 132, 6827-6833.
160. Mimasu, S.; Sengoku, T.; Fukuzawa, S.; Umehara, T.; Yokoyama, S. Crystal structure of histone demethylase LSD1 and tranylcypromine at 2.25 Å. Biochem. Biophys. Res. Commun., 2008, 366, 15-22.
161. Culhane, J. C.; Wang, D.; Yen, P. M.; Cole, P. A. Comparative analysis of small molecules and histone substrate analogues as LSD1 lysine demethylase inhibitors. J. Am. Chem. Soc., 2010, 132, 3164-3176.
162. Klose, R. J.; Zhang, Y. Regulation of histone methylation by demethylimination and demethylation. Nat. Rev. Mol. Cell Biol., 2007, 8, 307-318.
163. Couture, J.-F.; Collazo, E.; Ortiz-Tello, P. A.; Brunzelle, J. S.; Trievel, R. C. Specificity and mechanism of JMJD2A, a trimethyllysine-specific histone demethylase. Nat. Struct. Mol. Biol., 2007, 14, 689-695.
164. Ng, S. S.; Kavanagh, K. L.; McDonough, M. A.; Butler, D.; Pilka, E. S.; Lienard, B. M. R.; Bray, J. E.; Savitsky, P.; Gileadi, O.; von Delft, F.; Rose, N. R.; Offer, J.; Scheinost, J. C.; Borowski, T.; Sundstrom, M.; Schofield, C. J.; Opperman, U. Crystal structures of histone demethylase JMJD2A reveal basis for substrate specificity. Nature, 2007, 448, 87-91.
165. Chen, Z.; Zang, J.; JKappler, J.; Hong, X.; Crawford, F.; Wang, Q.; Lan, F.; Jiang, C.; Whetstine, J.; Dai, S.; K., H.; Shi, Y.; Zhang, G. Structural basis of the recognition of a methylated histone tail by JMJD2A. Proc. Natl. Acad. Sci. USA, 2007, 104, 10818-10823.
166. Loenarz, C.; Schofield, C. J. Expanding chemical biology of 2- oxoglutarate oxygenases. Nat. Chem. Biol., 2008, 4, 152-156.
167. Rose, N. R.; Ng, S. S.; MecinovicãÅ, J.; LieÃÅnard, B. M. R.; Bello, S. H.; Sun, Z.; McDonough, M. A.; Oppermann, U.; Schofield, C. J. Inhibitor scaffolds for 2-oxoglutarate- dependent histone lysine demethylases. J. Med. Chem., 2008, 51, 7053-7056.
168. Hamada, S.; Kim, T.-D.; Suzuki, T.; Itoh, Y.; Tsumoto, H.; Nakagawa, H.; Janknecht, R.; Miyata, N. Synthesis and activity of N-oxalylglycine and its derivatives as Jumonji C-domaincontaining histone lysine demethylase inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, 2852-2855.
169. Rose, N. R.; Woon, E. C. Y.; Kingham, G. L.; King, O. N. F.; MecinovicÃÅ, J.; Clifton, I. J.; Ng, S. S.; Talib-Hardy, J.; Oppermann, U.; McDonough, M. A.; Schofield, C. J. Selective inhibitors of the JMJD2 histone demethylases: Combined nondenaturing mass spectrometric screening and crystallographic approaches. J. Med. Chem., 2010, 53, 1810-1818.
170. Marks, P. A.; Breslow, R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat. Biotechnol., 2007, 25, 84-90.
171. Kelly, W. K.; O'Connor, O. A.; Krug, L. M.; Chiao, J. H.; Heaney, M.; Curley, T.; MacGregore- Cortelli, B.; Tong, W.; Secrist, J. P.; Schwartz, L.; Richardson, S.; Chu, E.; Olgac, S.; Marks, P. A.; Scher, H.; Richon, V. M. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol., 2005, 23, 3923-3931.
172. Rubin, E. H.; Agrawal, N. G.; Friedman, E. J.; Scott, P.; Mazina, K. E.; Sun, L.; Du, L.; Ricker, J. L.; Frankel, S. R.; Gottesdiener, K. M.; Wagner, J. A.; Iwamoto, M. A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. Clin. Cancer Res., 2006, 12, 7039-7045.
173. Sandor, V.; Bakke, S.; Robey, R. W.; Kang, M. H.; Blagosklonny, M. V.; Bender, J.; Brooks, R.; Piekarz, R. L.; Tucker, E.; Figg, W. D.; Chan, K. K.; Goldspiel, B.; Fojo, A. T.; Balcerzak, S. P.; Bates, S. E. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin. Cancer Res., 2002, 8, 718-728.
174. Garcia-Manero, G.; Yang, H.; Bueso-Ramos, C.; Ferrajoli, A.; Cortes, J.; Wierda, W. G.; Faderl, S.; Koller, C.; Morris, G.; Rosner, G.; Loboda, A.; Fantin, V. R.; Randolph, S. S.; Hardwick, J. S.; Reilly, J. F.; Chen, C.; Ricker, J. L.; Secrist, J. P.; Richon, V. M.; Frankel, S. R.; Kantarjian, H. M. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood, 2008, 111, 1060-1066.
175. Gojo, I.; Jiemjit, A.; Trepel, J. B.; Sparreboom, A.; Figg, W. D.; Rollins, S.; Tidwell, M. L.; Greer, J.; Chung, E. J.; Lee, M. J.; Gore, S. D.; Sausville, E. A.; Zwiebel, J.; Karp, J. E. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood, 2007, 109, 2781-2790.
176. Odenike, O. M.; Alkan, S.; Sher, D.; Godwin, J. E.; Huo, D.; Brandt, S. J.; Green, M.; Xie, J.; Zhang, Y.; Vesole, D. H.; Stiff, P.; Wright, J.; Larson, R. A.; Stock, W. Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia. Clin. Cancer Res., 2008, 14, 7095-7101.
177. Mann, B. S.; Johnson, J. R.; Cohen, M. H.; Justice, R.; Pazdur, R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist, 2007, 12, 1247-1252.
178. Olsen, E. A.; Kim, Y. H.; Kuzel, T. M.; Pacheco, T. R.; Foss, F. M.; Parker, S.; Frankel, S. R.; Chen, C.; Ricker, J. L.; Arduino, J. M.; Duvic, M. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous Tcell lymphoma. J. Clin. Oncol., 2007, 25, 3109-3115.
179. Pohlman, B.; Advani, R.; Duvic, M.; Hymes, K.; Intragumtornchai, T.; Lekhakula, A.; Shpilberg, O.; Lerner, A.; D, B.-Y.; Beylot- Barry, M.; Hillen, U.; Fagerberg, J.; Foss, F. M. Final results of a phase II trial of belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma ASH 51st Annual Meeting New Orleans, 2-5 Dec 2009, (920).
180. Bates, S. E.; Zhan, Z.; Steadman, K.; Obrzut, T.; Luchenko, V.; Frye, R.; Robey, R. W.; Turner, M.; Gardner, E. R.; Figg, W. D.; Steinberg, S. M.; Ling, A.; Fojo, T.; To, K. W.; Piekarz, R. L. Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. Br. J. Haematol., 2010, 148, 256-267.
181. Briones, J., Emerging therapies for B-cell non-Hodgkin lymphoma. Expert Rev. Anticancer Ther., 2009, 9, 1305-1316.
182. Dickinson, M.; Ritchie, D.; DeAngelo, D. J.; Spencer, A.; Ottmann, O. G.; Fischer, T.; Bhalla, K. N.; Liu, A.; Parker, K.; Scott, J. W.; Bishton, M.; Prince, H. M. Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma. Br. J. Haematol., 2009, 147, 97-101.
183. Bociek, R.; Kuruvilla, J. Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin Lymphoma (HL). J. Clin. Oncol., 2008, 26 (Abstract ASCO Meeting, 8507).
184. Younes, A.; Andreadis, C.; Assouline, S. Treatmentof relapsed or refractory non-hodgkin lymphomawith the oral isotype-selective histone deacetylase inhibitor MGCD0103: Interim results froma phase II study. Ann. Oncol. 2008, 19, 162 (Abstract).
185. Richardson, P.; Mitsiades, C.; Colson, K.; Reilly, E.; McBride, L.; Chiao, J.; Sun, L.; Ricker, J.; Rizvi, S.; Oerth, C.; Atkins, B.; Fearen, I.; Anderson, K.; Siegel, D. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk. Lymphoma, 2008, 49, 502-507.
186. Richardson, P. G.; San-Miguel, J.; Lonial, S.; Reece, D.; Jakubowiak, A.; Hussein, M.; Jagannath, S.; Mitsiades, C. S.; Raje, N.; Kaufman, J.; Avigan, D.; Ghobrial, I.; Schlossman, R. L.; Munshi, N.; Dalton, W.; Anderson, K. C. The research mission in myeloma. Leukemia, 2009, 23, 422-423.
187. Galli, M.; Salmoiraghi, S.; Golay, J.; Gozzini, A.; Crippa, C.; Pescosta, N.; Rambaldi, A. A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma. Ann. Hematol., 2010, 89, 185-190.
188. Harrison, S.; Quach, H.; Yuen, K. High response rates with the combination of bortezomib, dexamethasone and the pan-histone deacetylase inhibitor romidepsin in patients with relapsed or refractory multiple myeloma in a phase I/II clinical trial. ASH Annual Meeting 2008, 112, Abstracts 2008, 3698.
189. Siegel, D.; Sezer, O.; San Miguel, J. A phase IB, Multicenter, open-label, dose-escalation study of oral panobinostat (LBH589) and I.V. bortezomib in patients with relapsed multiple myeloma. ASH Annual Meeting 2008, Abstracts 2008, 112, 2781.
190. Marchion, D.; Munster, P. Development of histone deacetylase inhibitors for cancer treatment. Expert Rev. Anticancer Ther., 2007, 7, 583-98.
191. Rasheed, W.; Bishton, M.; Johnstone, R. W.; Prince, H. M. Histone deacetylase inhibitors in lymphoma and solid malignancies. Expert Rev. Anticancer Ther., 2008, 8, 413-432.
192. Jones, L. K.; Saha, V. Chromatin modification, leukaemia and implications for therapy. Br. J. Haematol., 2002, 118, 714-727.
193. Bishton, M.; Kenealy, M.; Johnstone, R.; Rasheed, W.; Prince, H. M. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents. Expert Rev. Anticancer Ther., 2007, 7, 1439-1449.
194. Camphausen, K.; Tofilon, P. J. Inhibition of histone deacetylation: a strategy for tumor radiosensitization. J. Clin. Oncol., 2007, 25, 4051-4056.
195. Hideshima, T.; Anderson, K. C. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat. Rev. Cancer, 2002, 2, 927-937.
196. Rodríguez-González, A.; Lin, T.; Ikeda, A. K.; Simms-Waldrip, T.; Fu, C.; Sakamoto, K. M. Role of the aggresome pathway in cancer: targeting histone deacetylase 6-dependent protein degradation. Cancer Res., 2008, 68, 2557-2560.
197. Kawaguchi, Y.; Kovacs, J. J.; McLaurin, A.; Vance, J. M.; Ito, A.; Yao, T. P. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell, 2003, 115, 727-738.
198. Maiso, P.; Carvajal-Vergara, X.; Ocio, E. M.; Lopez-Perez, R.; Mateo, G.; Gutiérrez, N.; Atadja, P.; Pandiella, A.; San Miguel, J. F. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res., 2006, 66, 5781-5789.
199. Nawrocki, S. T.; Carew, J. S.; Pino, M. S.; Highshaw, R. A.; Andtbacka, R. H.; Dunner, K., Jr.; Pal, A.; Bornmann, W. G.; Chiao, P. J.; Huang, P.; Xiong, H.; Abbruzzese, J. L.; McConkey, D. J. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res., 2006, 66, 3773-3781.
200. Borbone, E.; Berlingieri, M. T.; De Bellis, F.; Nebbioso, A.; Chiappetta, G.; Mai, A.; Altucci, L.; Fusco, A. Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation. Oncogene, 2010, 29, 105-116.
201. Boyault, C.; Zhang, Y.; Fritah, S.; Caron, C.; Gilquin, B.; Kwon, S. H.; Garrido, C.; Yao, T. P.; Vourc'h, C.; Matthias, P.; Khochbin, S. HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. Genes Dev., 2007, 21, 2172-2181.
202. Whitesell, L.; Lindquist, S. L. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer, 2005, 5, 761-772.
203. Giles, F.; Fischer, T.; Cortes, J.; Garcia-Manero, G.; Beck, J.; Ravandi, F.; Masson, E.; Rae, P.; Laird, G.; Sharma, S.; Kantarjian, H.; Dugan, M.; Albitar, M.; Bhalla, K. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin. Cancer Res., 2006, 12, 4628-4635.
204. Ellis, L.; Pan, Y.; Smyth, G. K.; George, D. J.; McCormack, C.; Williams-Truax, R.; Mita, M.; Beck, J.; Burris, H.; Ryan, G.; Atadja, P.; Butterfoss, D.; Dugan, M.; Culver, K.; Johnstone, R. W.; Prince, H. M. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin. Cancer Res., 2008, 14, 4500-4510.
205. Kim, Y.; Whittaker, S.; Demierre, M. Clinically significant responses achieved with romidepsin in treatment-refractory cutaneous T-cell lymphoma: final results from a phase 2B, international, multicenter, registration study. ASH Annual Meeting, 2008, Abstracts 2008;112-263.
206. Fantin, V. R.; Richon, V. M. Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications. Clin. Cancer Res., 2007, 13, 7237-7242.
207. Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem., 2005, 48, 6523-6543.
208. Meunier, B. Hybrid molecules with a dual mode of action: Dream or reality? Acc. Chem. Res., 2008, 41, 69-77.
209. Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed multiple ligands. Drug Disc. Today, 2004, 9, 641-651.
210. Chou, T. C.; Talalay, P. Quantitative analysis of dose-effects relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul., 1984, 22, 27-55.
211. Lai, C.-J.; Bao, R.; Tao, X.; Wang, J.; Atoyan, R.; Qu, H.; Wang, D.-G.; Yin, L.; Samson, M.; Forrester, J.; Zifcak, B.; Xu, G.-X.; DellaRocca, S.; Zhai, H.-X.; Cai, X.; Munger, W. E.; Keegan, M.; Pepicelli, C. V.; Qian, C. CUDC-101, a Multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer Res., 2010, 70, 3647-3656.
212. Mahboobi, S.; Dove, S.; Sellmer, A.; Winkler, M.; Eichhorn, E.; Pongratz, H.; Ciossek, T.; Baer, T.; Maier, T.; Beckers, T. Design of chimeric histone deacetylase- and tyrosine kinase- inhibitors: A series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR- ABL, PDGF-R, and histone deacetylases. J. Med. Chem., 2009, 52, 2265-2279.
213. Hynes, N. E.; Lane, H. ERBB Receptors and cancer: The complexity of targeted inhibitors. Nat. Rev. Cancer, 2005, 5, 341-354.
214. Cai, X.; Zhai, H.-X.; Wang, J.; Forrester, J.; Qu, H.; Yin, L.; Lai, C.-J.; Bao, R.; Qian, C. Discovery of 7-(4-(3-ethynylphenylamino)- 7-methoxyquinazolin-6-yloxy)-N- hydroxyheptanamide (CUDC- 101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer. J. Med. Chem., 2010, 53, 2000-2009.
215. Kozikowski, A. P.; Chen, Y.; Subhasish, T.; Lewin, N. E.; Blumberg, P. M.; Zhong, Z.; D'Annibale, M. A.; Wang, W.-L.; Shen, Y.; Langley, B. Searching for disease modifiers- PKC activation and HDAC inhibition-A dual drug approach to Alzheimer's disease that decreases Abeta production while blocking oxidative stress. ChemMedChem, 2009, 4, 1095-1105.
216. Hedstrom, L.; Gan, L. IMP dehydrogenase: structural schizophrenia and an unusual base. Curr. Opin. Chem. Biol., 2006, 10, 520-525.
217. Chen, L.; Wilson, D.; Jayaram, H. N.; Pankiewicz, K. W. Dual Inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment. J. Med. Chem., 2007, 50, 6685-6691.
218. Tavera-Mendoza, L. E.; Quach, T. D.; Dabbas, B.; Hudon, J.; Liao, X.; Palijan, A.; Gleason, J. L.; White, J. H. Incorporation of histone deacetylase inhibition into the structure of a nuclear receptor agonist. Proc. Natl. Acad. Sci. USA, 2008, 105, 8250-8255.
219. Lamblin, M.; Dabbas, B.; Spingarn, R.; Mendoza-Sánchez, R.; Wang, T.-T.; An, B.-S.; Huang, D. C.; Kremer, R.; White, J. H.; Gleason, J. L. Vitamin D receptor agonist/histone deacetylase inhibitor molecular hybrids. Bioorg. Med. Chem., 2010, 18, 4119 4137.
220. Griffith, D.; Morgan, M. P.; Marmion, C. J. A novel anti-cancer bifunctional platinum drug candidate with dual DNA binding and histone deacetylase inhibitory activity. Chem. Commun., 2009, 6735-6737.
221. Passarella, D.; Comi, D.; Vanossi, A.; Paganini, G.; Colombo, F.; Ferrante, L.; Zuco, V.; Danieli, B.; Zunino, F. Histone deacetylase and microtubulesas targets for the synthesis of releasable conjugate compounds. Bioorg. Med. Chem. Lett., 2009, 19, 6358-6363.
222. Dowdy, S. C.; Jiang, S.; Zhou, X. C.; Hou, X.; Jin, F.; Podratz, K. C.; Jiang, S.-W. Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Mol. Cancer Ther., 2006, 5, 2767-2776.
223. Nudelman, A.; Raphaeli, A. Novel mutual prodrugs of retinoic and butyric acids with enhanced anticancer activity. J. Med. Chem., 2000, 43, 2962-2966.
224. Gediya, L. K.; Khandelwal, A.; Patel, J.; Belosay, A.; Sabnis, G.; Mehta, J.; Purushottamachar, P.; Njar, V. C. O. Design, synthesis, and evaluation of novel mutual prodrugs (hybrid drugs) of alltrans- retinoic acid and histone deacetylase inhibitors with enhanced anticancer activities in breast and prostate cancer cells in vitro. J. Med. Chem., 2008, 51, 3895-3904.
225. Fliri, A. F.; Loging, W. T.; Volkmann, R. A. Drug effects viewed from a signal transduction network perspective. J. Med. Chem., 2009, 52, 8038-8046.
226. Keiser, M. J.; Setola, V.; Irwin, J. J.; Laggner, C.; Abbas, A. I.; Hufeisen, S. J.; Jensen, N. H.; Kuijer, M. B.; Matos, R. C.; Tran, T. B.; Whaley, R.; Glennon, R. A.; Hert, J.; Thomas, K. L. H.; Edwards, D. D.; Shoichet, B. K.; Roth, B. L. Predicting new molecular targets for known drugs. Nature, 2009, 462, 175-183.
227. Wu, L.-P.; Wang, X.; Li, L.; Zhao, Y.; Lu, S.; Yu, Y.; Zhou, W.; Liu, X.; Yang, J.; Zheng, Z.; Zhang, H.; Feng, J.; Yang, Y.; Wang, H.; Zhu, W.-G. Histone deacetylase inhibitor depsipeptide activates silenced genes through decreasing both CpG and H3K9 methylation on the promoter. Mol. Cell. Biol., 2008, 28, 3219-3235.
228. You, J. S.; Kang, J. K.; Lee, E. K.; Lee, J. C.; Lee, S. H.; Jeon, Y. J.; Koh, D. H.; Ahn, S. H.; Seo, D. W.; Lee, H. Y.; Cho, E. J.; Han, J. W. Histone deacetylase inhibitor apicidin downregulates DNA methyltransferase 1 expression and induces repressive histone modifications via recruitment of corepressor complex to promoter region in human cervix cancer cells. Oncogene, 2007, 27, 1376-1386.
229. Zhou, Q.; Agoston, A. T.; Atadja, P.; Nelson, W. G.; Davidson, N. E. Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells. Mol. Cancer Res., 2008, 6, 873-883.
230. Fiskus, W.; Pranpat, M.; Balasis, M.; Herger, B.; Rao, R.; Chinnaiyan, A.; Atadja, P.; Bhalla, K. Histone deacetylase inhibitors deplete enhacer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Mol. Cancer Ther., 2006, 5, 3096-3104.
231. Mai, A.; Cheng, D.; Bedford, M. T.; Valente, S.; Nebbioso, A.; Perrone, A.; Brosch, G.; Sbardella, G.; De Bellis, F.; Miceli, M.; Altucci, L. Epigenetic multiple ligands: Mixed histone/protein methyltransferase, acetyltransferase, and class III deacetylase (Sirtuin) inhibitors. J. Med. Chem., 2008, 51, 2279-2290.
232. Selvi B, R.; Pradhan, S. K.; Shandilya, J.; Das, C.; Sailaja, B. S.; Shankar G, N.; Gadad, S. S.; Reddy, A.; Dasgupta, D.; Kundu, T. K. Sanguinarine interacts with chromatin, modulates epigenetic modifications, and transcription in the context of chromatin. Chem. Biol., 2009, 16, 203-216.
233. Piña, I. C.; Gautschi, J. T.; Wang, G. Y. S.; Sanders, M. L.; Schmitz, F. J.; France, D.; Cornell- Kennon, S.; Sambucetti, L. C.; Remiszewski, S. W.; Pérez, L. B.; Bair, K. W.; Crews, P. Psammaplins from the sponge Pseudoceratina purpurea: Inhibition of both histone deacetylase and DNA methyltransferase. J. Org. Chem., 2003, 68, 3866-3873.
234. Dey, A.; Tergaonkar, V.; Lane, D. P. Double-edged swords as cancer therapeutics: simultaneosuly targeting p53 and NF-kB pathways. Nat. Rev. Drug Discov., 2008, 7, 1031-1040.
235. Geva-Zatorsky, N.; Dekel, E.; Cohen, A. A.; Danon, T.; Cohen, L.; Alon, U. Protein dynamics in drug combinations: A linear superposition of individual-drug responses. Cell, 2010, 140, 643-651.